NASDAQ:CRSP | Free Cash Flow | CRISPR Therapeutics AG

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2014-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$108.9M$504,000.00-$109.4M
2025-12-31-$92.55M$517,000.00-$93.07M
2025-03-31-$53.95M$206,000.00-$54.15M
2024-12-31-$50.03M$254,000.00-$50.29M
2024-03-31$109.75M$721,000.00$109.03M
2023-12-31-$96.07M$738,000.00-$96.81M-108.35%
2023-03-31$8.8M$3.06M$5.74M
2022-12-31-$113.33M$6.19M-$119.52M
2022-03-31-$135.24M$15.35M-$150.59M
2021-12-31-$86.04M$9.18M-$95.22M
2021-03-31-$100.66M$7.02M-$107.69M
2020-12-31-$81.21M$6.24M-$87.45M
2020-03-31-$52.18M$2.99M-$55.17M
2019-12-31$3.38M$952,000.00$2.42M7.94%
2019-03-31-$43.74M$1.1M-$44.83M
2018-12-31-$28.37M$1M-$29.37M
2018-03-31-$22.69M$555,000.00-$23.24M
2017-12-31-$14.84M$205,000.00-$15.05M-10671.63%
2017-03-31-$23.41M$3.29M-$26.7M
2016-12-31-$16.97M$228,000.00-$17.19M-100.56%
2016-03-31-$10.01M$232,000.00-$10.25M
2015-12-31$69M$503,000.00$68.5M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$345.01M$914,000.00-$345.93M
2024-12-31-$142.77M$1.9M-$144.68M
2023-12-31-$260.38M$9.47M-$269.85M
2022-12-31-$495.74M$37.19M-$532.93M
2021-12-31$538.97M$81.71M$457.27M121.08%
2020-12-31-$238.37M$18.36M-$256.72M
2019-12-31$56.68M$6.68M$49.99M74.77%
2018-12-31-$96.24M$2.77M-$99.01M
2017-12-31-$70.09M$7.81M-$77.91M
2016-12-31-$52.86M$3.02M-$55.88M
2015-12-31$59.43M$1.15M$58.27M
2014-12-31-$4.79M